{"ticker": {"uuid": "43122979-d7af-4881-a94a-141f00866826", "symbol": "FDMT", "name": "4D Molecular Therapeutics\u00a0Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "4D Molecular Therapeutics (NASDAQ: FDMT) insider executes 58K-share 10b5-1 sale", "summary": "David Kirn, a director and officer at 4D Molecular Therapeutics (NASDAQ: FDMT), sold a total of 58,333 shares of common stock on July 9-10, 2026, under a Rule 10b5-1 trading plan. The sales occurred at weighted average prices between $12.0107 and $12.8656 per share. Following the", "url": "https://www.stocktitan.net/sec-filings/FDMT/form-4-4d-molecular-therapeutics-inc-insider-trading-activity-695617e26302.html", "source_name": "Stock Titan", "published_at": "2026-07-15T16:40:29", "published_display": "15 Jul 2026 16:40", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4d Molecular Therapeutics CEO David Kirn sells $737k in stock", "summary": "David Kirn, CEO of 4D Molecular Therapeutics (NASDAQ:FDMT), sold shares worth over $737,000 on July 9 and 10, 2026, as part of a pre-arranged trading plan. This sale occurred while the company's stock experienced volatility, despite a significant annual return and an InvestingPro", "url": "https://ng.investing.com/news/stock-market-news/4d-molecular-therapeutics-ceo-david-kirn-sells-737k-in-stock-93CH-2599620", "source_name": "Investing.com Nigeria", "published_at": "2026-07-14T21:40:30", "published_display": "14 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Form 144 4D Molecular Therapeutics For: 10 July By Investing.com", "summary": "This article announces a Form 144 filing for 4D Molecular Therapeutics (FDMT) made on July 10, 2026. The brief entry provides the filing date and company name, indicating an insider transaction or proposed sale of securities, and lists the stock's performance with a -4.50% change", "url": "https://ng.investing.com/news/stock-market-news/form-144-4d-molecular-therapeutics-for-10-july-93CH-2595650", "source_name": "Investing.com Nigeria", "published_at": "2026-07-10T22:26:00", "published_display": "10 Jul 2026 22:26", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "David Kirn sells Class A shares for FDMT (FDMT) in June 2026", "summary": "David Kirn, an insider at 4D Molecular Therapeutics, Inc. (FDMT), reported two sales of Class A Common shares in June 2026. On June 1, 2026, he sold 1,922 shares for $19,257.86, and on June 22, 2026, he sold 114,746 shares for $1,200,851.31. These shares were originally acquired ", "url": "https://www.stocktitan.net/sec-filings/FDMT/144-4d-molecular-therapeutics-inc-sec-filing-88b9acf188c3.html", "source_name": "Stock Titan", "published_at": "2026-07-09T21:41:50", "published_display": "09 Jul 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDMT - 4D Molecular Therapeutics Inc Revenue Breakdown", "summary": "This article provides a detailed financial breakdown for 4D Molecular Therapeutics Inc. (FDMT), including key metrics such as market cap, sales, income, EPS, and various performance indicators. It also lists insider and institutional ownership, short interest, and analyst recomme", "url": "https://finviz.com/stock?t=FDMT&b=2&p=d&ty=rv", "source_name": "Finviz", "published_at": "2026-07-06T18:13:35", "published_display": "06 Jul 2026 18:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDMT - 4D Molecular Therapeutics Inc Forecast, Target Price", "summary": "This article provides a detailed financial overview and forecast for 4D Molecular Therapeutics Inc (FDMT), including its stock performance, key financial metrics, insider and institutional ownership, and analyst recommendations. The company currently has a target price of $27.62 ", "url": "https://finviz.com/quote.ashx?t=FDMT&b=2&p=d&ty=fc", "source_name": "Finviz", "published_at": "2026-07-06T16:13:35", "published_display": "06 Jul 2026 16:13", "sentiment": "positive", "sentiment_pct": 59, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of 4D Molecular Therapeutics, Inc. \u2013 NASDAQ:FDMT", "summary": "This article provides the \"Price to earnings forward\" for 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) on TradingView. It appears to be an auto-generated or financial data stub page, displaying the company's stock information and financial metrics within the TradingView platfor", "url": "https://www.tradingview.com/symbols/NASDAQ-FDMT/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T03:39:34", "published_display": "05 Jul 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDMT (NASDAQ: FDMT) CLO sells 6,566 shares, exercises options under 10b5-1 plan", "summary": "4D Molecular Therapeutics Chief Legal Officer Scott Bizily sold 6,566 shares of common stock at $14.00 per share on June 30, 2026, as part of a Rule 10b5-1 trading plan. On the same date, he exercised stock options for a total of 6,566 shares at exercise prices of $6.49 and $4.14", "url": "https://www.stocktitan.net/sec-filings/FDMT/form-4-4d-molecular-therapeutics-inc-insider-trading-activity-a22f78de47b3.html", "source_name": "Stock Titan", "published_at": "2026-07-02T19:42:17", "published_display": "02 Jul 2026 19:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 4D Molecular Therapeutics For: 30 June By Investing.com", "summary": "This article from Investing.com reports the filing of Form 144 for 4D Molecular Therapeutics activity as of June 30. The content is very brief, serving primarily as a notice of the filing. It is surrounded by extensive financial market data, news headlines, and navigational eleme", "url": "https://ca.investing.com/news/stock-market-news/form-144-4d-molecular-therapeutics-for-30-june-93CH-4714990", "source_name": "Investing.com Canada", "published_at": "2026-07-01T12:10:40", "published_display": "01 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDMT - 4D Molecular Therapeutics Inc Latest SEC Filings", "summary": "This page provides a detailed financial overview and snapshot of 4D Molecular Therapeutics Inc (FDMT), including its latest stock performance, key financial metrics, insider and institutional ownership, and valuation ratios. The data highlights the company's recent strong perform", "url": "https://finviz.com/stock?t=FDMT&ta=1&p=w&ty=lf&page=3", "source_name": "Finviz", "published_at": "2026-07-01T12:10:40", "published_display": "01 Jul 2026 12:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4D Molecular Therapeutics to present 2-year Phase 2b trial results of gene therapy 4D-150 for wet AMD at ASRS 2026", "summary": "4D Molecular Therapeutics announced it will present two-year follow-up data from its PRISM Phase 2b clinical trial of 4D-150, a gene therapy for wet age-related macular degeneration (AMD), at the 44th Annual Scientific Meeting of the American Society of Retina Specialists in July", "url": "https://pluang.com/en/news-feed/4dmt-umumkan-presentasi-di-pertemuan-ilmiah-american-society-of-retina", "source_name": "Pluang", "published_at": "2026-06-30T20:39:46", "published_display": "30 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 90, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDMT (NASDAQ: FDMT) insider 10b5-1 sale of 9,810 shares for $117,720", "summary": "An affiliate of 4D Molecular Therapeutics, Inc. (FDMT) filed a Form 144 detailing insider sales. The filing reports a 10b5-1 sale by Scott Bizily of 9,810 shares for $117,720 on June 23, 2026, alongside an exercise of stock options for 5,752 shares and an Employee Stock Purchase ", "url": "https://www.stocktitan.net/sec-filings/FDMT/144-4d-molecular-therapeutics-inc-sec-filing-9caaaa8975e5.html", "source_name": "Stock Titan", "published_at": "2026-06-30T20:39:46", "published_display": "30 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists", "summary": "4D Molecular Therapeutics (4DMT) announced a podium presentation at the 44th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) in Montreal, Canada, from July 15-18, 2026. The presentation will provide a 2-year follow-up on the PRISM Phase 2b clinical ", "url": "https://www.globenewswire.com/news-release/2026/06/30/3320101/0/en/4dmt-announces-presentation-at-44th-annual-scientific-meeting-of-the-american-society-of-retina-specialists.html", "source_name": "GlobeNewswire", "published_at": "2026-06-30T19:39:46", "published_display": "30 Jun 2026 19:39", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4DMT to present 2-year PRISM trial follow-up at retina meeting", "summary": "4D Molecular Therapeutics (Nasdaq: FDMT) has announced a podium presentation at the 44th Annual Scientific Meeting of the American Society of Retina Specialists on July 18, 2026. The presentation will feature two-year follow-up data from the PRISM Phase 2b trial of its investigat", "url": "https://www.stocktitan.net/news/FDMT/4dmt-announces-presentation-at-44th-annual-scientific-meeting-of-the-6hosb21ldhft.html", "source_name": "Stock Titan", "published_at": "2026-06-30T19:39:46", "published_display": "30 Jun 2026 19:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4DMT completes enrollment in 4FRONT-2, global phase 3 trial of 4D-150 in wet AMD", "summary": "4D Molecular Therapeutics (4DMT) has completed enrollment in 4FRONT-2, a global Phase 3 trial for its gene therapy 4D-150 in patients with wet age-related macular degeneration (AMD). This over-enrollment, completed four months ahead of schedule, underscores significant interest i", "url": "https://www.ophthalmologytimes.com/view/4dmt-completes-enrollment-in-4front-2-global-phase-3-trial-of-4d-150-in-wet-amd", "source_name": "Ophthalmology Times", "published_at": "2026-06-30T14:40:54", "published_display": "30 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4DMT Completes 4FRONT-2 Enrollment for 4D-150 Gene Therapy in Wet AMD", "summary": "4D Molecular Therapeutics has completed enrollment for its global Phase 3 trial, 4FRONT-2, for the gene therapy candidate 4D-150 in wet age-related macular degeneration, four months ahead of schedule. The trial aims to achieve non-inferiority in visual acuity compared to afliberc", "url": "https://www.clinicaltrialvanguard.com/news/4dmt-completes-4front-2-enrollment-for-4d-150-gene-therapy-in-wet-amd/", "source_name": "The Clinical Trial Vanguard", "published_at": "2026-06-30T06:39:30", "published_display": "30 Jun 2026 06:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4DMT Secures Strategic Credit Facility for up to $200MM from Hercules Capital", "summary": "4D Molecular Therapeutics (4DMT) has secured a strategic credit facility of up to $200 million from Hercules Capital. This non-dilutive capital is expected to provide 4DMT with increased financial flexibility, supporting its operations into the second half of 2028 and advancing i", "url": "https://www.abfjournal.com/4dmt-secures-strategic-credit-facility-for-up-to-200mm-from-hercules-capital/", "source_name": "ABF Journal", "published_at": "2026-06-30T04:39:30", "published_display": "30 Jun 2026 04:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4D Molecular Therapeutics Shares Rise After New Credit Facility", "summary": "4D Molecular Therapeutics (NASDAQ:FDMT) shares increased following the announcement of a new Senior Secured Credit Facility worth $175 million from an investment fund managed by Blue Owl Capital. This financing is expected to extend the company's cash runway into 2027 and support", "url": "https://www.moomoo.com/news/post/72199244/4d-molecular-therapeutics-shares-rise-after-new-credit-facility", "source_name": "Moomoo", "published_at": "2026-06-30T01:40:53", "published_display": "30 Jun 2026 01:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: 4DMT Secures Strategic Credit Facility for up to $200 Million From Hercules Capital", "summary": "4D Molecular Therapeutics (4DMT) has secured a strategic credit facility for up to $200 million from Hercules Capital. This financing is intended to support the company's clinical pipeline development, including its lead product candidates, and provide working capital. The facili", "url": "https://www.moomoo.com/news/post/72189834/press-release-4dmt-secures-strategic-credit-facility-for-up-to", "source_name": "Moomoo", "published_at": "2026-06-30T00:42:17", "published_display": "30 Jun 2026 00:42", "sentiment": "positive", "sentiment_pct": 71, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4DMT SECURES STRATEGIC CREDIT FACILITY FOR UP TO $200 MILLION FROM HERCULES CAPITAL", "summary": "4D Molecular Therapeutics (4DMT) has secured a credit facility of up to $200 million from Hercules Capital. This funding is intended to support the clinical development and manufacturing of 4DMT's targeted AAV gene therapy pipeline, particularly focusing on late-stage clinical pr", "url": "https://www.moomoo.com/news/flash/22715160/4dmt-secures-strategic-credit-facility-for-up-to-200-million", "source_name": "Moomoo", "published_at": "2026-06-29T19:11:55", "published_display": "29 Jun 2026 19:11", "sentiment": "positive", "sentiment_pct": 82, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4D Molecular Therapeutics Completes Enrollment in Phase 3 Wet AMD Trial", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/4d-molecular-therapeutics-completes-enrollment-124323164.html", "source_name": "MT Newswires", "published_at": "2026-06-29T12:43:23+00:00", "published_display": "29 Jun 2026 12:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4D Molecular Therapeutics Completes Enrollment for 4Front-2 Global Phase 3 Clinical Trial of 4D-150 in Wet Amd", "summary": "4D Molecular Therapeutics has completed enrollment for its 4FRONT-2 global Phase 3 clinical trial of 4D-150 for wet age-related macular degeneration (wet AMD) approximately four months ahead of schedule. The trial over-enrolled patients, with final randomization expected in Q3 20", "url": "https://www.marketscreener.com/news/4d-molecular-therapeutics-completes-enrollment-for-4front-2-global-phase-3-clinical-trial-of-4d-150-ce7f5fded08ef323", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T13:11:54", "published_display": "29 Jun 2026 13:11", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4D Molecular Therapeutics (FDMT) signs up to $200M secured loan with Hercules", "summary": "4D Molecular Therapeutics, Inc. (FDMT) has secured a senior loan of up to $200 million from Hercules Capital, with an initial draw of $20 million and additional tranches tied to milestones. The loan matures on June 1, 2031, carries floating interest rates with floors of 8.75% to ", "url": "https://www.stocktitan.net/sec-filings/FDMT/8-k-4d-molecular-therapeutics-inc-reports-material-event-aa25bfd37ca4.html", "source_name": "Stock Titan", "published_at": "2026-06-29T12:11:55", "published_display": "29 Jun 2026 12:11", "sentiment": "positive", "sentiment_pct": 61, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4DMT finishes Phase 3 enrollment for wet AMD gene therapy trial", "summary": "4D Molecular Therapeutics (4DMT) has completed enrollment for its 4FRONT-2 global Phase 3 clinical trial for 4D-150 in wet AMD, approximately four months ahead of schedule and with over 500 patients. This milestone, along with the ongoing 4FRONT-1 trial, positions 4DMT to potenti", "url": "https://www.stocktitan.net/news/FDMT/4dmt-completes-enrollment-for-4front-2-global-phase-3-clinical-trial-9hbsdoided79.html", "source_name": "Stock Titan", "published_at": "2026-06-29T12:11:54", "published_display": "29 Jun 2026 12:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD", "summary": "4D Molecular Therapeutics (4DMT) announced the completion of enrollment for its 4FRONT-2 global Phase 3 clinical trial of 4D-150 for wet age-related macular degeneration (wet AMD), approximately four months ahead of schedule and with over-enrollment. This marks the second complet", "url": "https://www.globenewswire.com/news-release/2026/06/29/3318897/0/en/4dmt-completes-enrollment-for-4front-2-global-phase-3-clinical-trial-of-4d-150-in-wet-amd.html", "source_name": "GlobeNewswire", "published_at": "2026-06-29T12:11:54", "published_display": "29 Jun 2026 12:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4D Molecular (NASDAQ: FDMT) CLO exercises options, sells 9,810 shares at $12", "summary": "4D Molecular Therapeutics' Chief Legal Officer, Scott Bizily, exercised options to acquire 9,810 shares at $4.14 per share and then sold all of them on the open market at $12.00 per share on June 23, 2026. Following these transactions, Bizily holds 18,427 common shares directly a", "url": "https://www.stocktitan.net/sec-filings/FDMT/form-4-4d-molecular-therapeutics-inc-insider-trading-activity-9fb6a7e1d03f.html", "source_name": "Stock Titan", "published_at": "2026-06-25T20:39:18", "published_display": "25 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Strength Seen in 4D Molecular Therapeutics (FDMT): Can Its 7.9% Jump Turn into More Strength?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQZDR2V2UyZFltdXprY3FlUktWNnRUdVdlaFJsVVhZeHlTMV9vRkxQRnMwREtIUW9xdVNqWWZjUDI5cjV2M2U0SXpFWWJ6ZzQwNVczR3AwWklPSnhFbG05LTVUQWtnaGJEOVY4R2dCUUwwQTBIbTRJYmdadE5zSk1iS0FYd0ExXzFhNFN5RVYyeDlZRnZmbFJpWkJaMC1IbHZobFJrSDAzQQ?oc=5", "source_name": "Market source", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider David Kirn sells 114,746 4D Molecular Therapeutics (FDMT) shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOUWJtZ0ZxYllZRE00elBGbHptR0NxTV84cmxVVUxOQWlKN0lnMFY2WVhPckZwTmZrY0tSMGJQRzdVTlZqbWFlcUVYOGFFN19RM3hZbHJGSkx4YlZWZlJ6amduaGgtVENtalg5dlhOa2JKeEFFRUVkcE90T0owUHQ0SlRUVWViNkFlRUExTkx3OVFJMlA1MXIwaHdjVGFHSDRIT09seDZkczhiaFJyWElJdngtSWE0SUhEaHRIbjRDZFQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4D Molecular Therapeutics (FDMT) director granted 50,000 stock options with CIC vesting", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPenVTLTQ1M3FBcmFpWkFneGUwdEtqMk1uYXJhM0hnMXA2MFZGNEFuYW1BTUtkTmpla1Y3UmFheEpFZmc5cS1NbUZNTDViZUVuck5iRDNzd1pmeDltZm5jaG4wbVB0OTc0c1dsYUtNUXJIMmFHcjZuZndyU2xPRlN0Rm5Rc3l0dDE5TTU3Y2RDdy1aNkdDWTN0M0JyZ0NMMnNTMmE4bmdJT3hwMkNUSWlBNnFBYjF1eFV4NHdwa0N5OUg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4D Molecular (FDMT) grants director 50,000 stock options at $9.42", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOb2JfN01IN0dpSEpoS0pRVzAxNnJ6TG9iaVBFRDZrYkJHc0pXUU9FS0pia3FnQmI0dWE5VExjdkE5RTB2MGdjNEZFdnMzUFo0aHY0aVpVSHZrcWgwcjJ3NDV2dTZoMHR5dmdOaTJTWXg1cUdDZ2U5SGtRazM2YUxmbkVJSDJmMlVZVVpsai1JYW9yaE1sdjlyXzZVai1lSnMwMzI4UWduU3RGaV9XcFJURzhTbUNyTl9NMlVXQy1pT0Y?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4D Molecular Therapeutics Inc (FDMT): Gene Therapy Stock Made for You?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNcURKLWlCMXE2dDZXWGxrbEpObmpONUg4ek5fZWtrVXNva1AwNDFDXzZmZTJ6THh0dVpJd3RHQjhLWnFBZnFtelZ1ckFxWENLSFlpRG56SVl1TDh1Zl8zaURhR3M0SG42ZGtlbThpdXdmVXYzWFZBTnE4X0xOR21NU2xvT2V3dDlvdXRfdG9jSFhHWjB6eEZRanUxY0VGWUtWMWFERV9n?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Analysts Have Made A Financial Statement On 4D Molecular Therapeutics, Inc.'s (NASDAQ:FDMT) First-Quarter Report", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQNXdJMG0yN2ZWQ1p5eXpUU1B4bWRIYURuR1RDYWI0QS1NZHUxVHR5aFpGaGVpWGpFYmhmckx5MnRUb2ZkaFljX2tCeW5pZ25NSFNLU1d2OTAxakhacGd2QzFxbVFJQVI2TWRRX2hQcEsydjQ1MEZnRnE1cTVsVnJsZ0ZfQXo5MjJMSlE2cm5CdEZUa1NvcFVoWjRGcUNkc25La1pr?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQNHBoRWVVYmp2SUpCX3ZmWjhxMDFVUVdwSE5kSzlpdDh4UTdKTC1kLXpZNy0xLU1SLVJ2RUNBc212SVJDbU1CREJqZzRLZzMwd2pYQlFaR0FHRGgyVEhVclpfTzMtNXFVRXVtc1dEV25xN3JvWGhRblBBeGVFRmttWmktcktVeC0tdXFZVVBpZHNkblVMYTlTUzRNb2t6RjdnS1pZQUhR?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "4D Molecular Therapeutics, Inc. Common Stock (FDMT) Stock Price Today: $11.70", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE9NMF9INXdqMlROanpUTUswMk5uVFdsN282X1htMEZ5NklmSXJEUDZVNmdlS2NZWkRsRWV2aExzRUY1WHVWYkhUOU13TmhlbDd0b3lUYTVoYw?oc=5", "source_name": "Gotrade", "published_at": "2026-01-13T02:30:02+00:00", "published_display": "13 Jan 2026 02:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Everyone Is Watching 4D Molecular Therapeutics, Inc. (FDMT) Closely", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxQZGdmbENQQlNiZnZENGs4NG95Z3c1QXoxWmFoOGxZdHlMMm9jLVZaZUxkUDZwMkZzZG10Ni1rNnlMTUdkLU1RY2lMaG43NVdHY054QzU2UHVfTjJPQjJyX3ZPV3BQNE1uWm1EdVFHcFE3aFFJOGZvSDNOWjkwQ3h4OVlvOWdCQU0?oc=5", "source_name": "Market source", "published_at": "2025-12-27T08:00:00+00:00", "published_display": "27 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is 4D Molecular Therapeutics (NASDAQ:FDMT) In A Good Position To Invest In Growth?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxOSlptUzBCRTAzdTNtZXl5U1BGMndia2RhQzdZc2txOTNvb2YtWGlzX3QyZjlBQ0xiV1h4OGR2eGpBRFN6dmJ3eFJja2tDenMwQ2kxR015ekZJd0wya1dxMXBWaGVhMjl0d3RXWkxqQWs3RGhKRzNIWTRLdTBucHNMU2ZCaC1ITmk1V2Zv?oc=5", "source_name": "Market source", "published_at": "2025-10-03T07:00:00+00:00", "published_display": "03 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4D Molecular Therapeutics (FDMT) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFB1VnBKcEFzMHFhQmltSE9zQ3NMX2tUY3Flb3BaZVVDcktZNjZpcjJBc0pnTnhNR1daQmVaMzFHa0s3cmcyb0VrVmhFWDBpY0RBMmZz?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T01:19:59+00:00", "published_display": "25 Apr 2025 01:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "4D Molecular Therapeutics (NASDAQ: FDMT) insider executes 58K-share 10b5-1 sale", "summary": "David Kirn, a director and officer at 4D Molecular Therapeutics (NASDAQ: FDMT), sold a total of 58,333 shares of common stock on July 9-10, 2026, under a Rule 10b5-1 trading plan. The sales occurred at weighted average prices between $12.0107 and $12.8656 per share. Following the", "url": "https://www.stocktitan.net/sec-filings/FDMT/form-4-4d-molecular-therapeutics-inc-insider-trading-activity-695617e26302.html", "source_name": "Stock Titan", "published_at": "2026-07-15T16:40:29", "published_display": "15 Jul 2026 16:40", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4d Molecular Therapeutics CEO David Kirn sells $737k in stock", "summary": "David Kirn, CEO of 4D Molecular Therapeutics (NASDAQ:FDMT), sold shares worth over $737,000 on July 9 and 10, 2026, as part of a pre-arranged trading plan. This sale occurred while the company's stock experienced volatility, despite a significant annual return and an InvestingPro", "url": "https://ng.investing.com/news/stock-market-news/4d-molecular-therapeutics-ceo-david-kirn-sells-737k-in-stock-93CH-2599620", "source_name": "Investing.com Nigeria", "published_at": "2026-07-14T21:40:30", "published_display": "14 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 4D Molecular Therapeutics For: 10 July By Investing.com", "summary": "This article announces a Form 144 filing for 4D Molecular Therapeutics (FDMT) made on July 10, 2026. The brief entry provides the filing date and company name, indicating an insider transaction or proposed sale of securities, and lists the stock's performance with a -4.50% change", "url": "https://ng.investing.com/news/stock-market-news/form-144-4d-molecular-therapeutics-for-10-july-93CH-2595650", "source_name": "Investing.com Nigeria", "published_at": "2026-07-10T22:26:00", "published_display": "10 Jul 2026 22:26", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "David Kirn sells Class A shares for FDMT (FDMT) in June 2026", "summary": "David Kirn, an insider at 4D Molecular Therapeutics, Inc. (FDMT), reported two sales of Class A Common shares in June 2026. On June 1, 2026, he sold 1,922 shares for $19,257.86, and on June 22, 2026, he sold 114,746 shares for $1,200,851.31. These shares were originally acquired ", "url": "https://www.stocktitan.net/sec-filings/FDMT/144-4d-molecular-therapeutics-inc-sec-filing-88b9acf188c3.html", "source_name": "Stock Titan", "published_at": "2026-07-09T21:41:50", "published_display": "09 Jul 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDMT - 4D Molecular Therapeutics Inc Revenue Breakdown", "summary": "This article provides a detailed financial breakdown for 4D Molecular Therapeutics Inc. (FDMT), including key metrics such as market cap, sales, income, EPS, and various performance indicators. It also lists insider and institutional ownership, short interest, and analyst recomme", "url": "https://finviz.com/stock?t=FDMT&b=2&p=d&ty=rv", "source_name": "Finviz", "published_at": "2026-07-06T18:13:35", "published_display": "06 Jul 2026 18:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDMT - 4D Molecular Therapeutics Inc Forecast, Target Price", "summary": "This article provides a detailed financial overview and forecast for 4D Molecular Therapeutics Inc (FDMT), including its stock performance, key financial metrics, insider and institutional ownership, and analyst recommendations. The company currently has a target price of $27.62 ", "url": "https://finviz.com/quote.ashx?t=FDMT&b=2&p=d&ty=fc", "source_name": "Finviz", "published_at": "2026-07-06T16:13:35", "published_display": "06 Jul 2026 16:13", "sentiment": "positive", "sentiment_pct": 59, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of 4D Molecular Therapeutics, Inc. \u2013 NASDAQ:FDMT", "summary": "This article provides the \"Price to earnings forward\" for 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) on TradingView. It appears to be an auto-generated or financial data stub page, displaying the company's stock information and financial metrics within the TradingView platfor", "url": "https://www.tradingview.com/symbols/NASDAQ-FDMT/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T03:39:34", "published_display": "05 Jul 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDMT (NASDAQ: FDMT) CLO sells 6,566 shares, exercises options under 10b5-1 plan", "summary": "4D Molecular Therapeutics Chief Legal Officer Scott Bizily sold 6,566 shares of common stock at $14.00 per share on June 30, 2026, as part of a Rule 10b5-1 trading plan. On the same date, he exercised stock options for a total of 6,566 shares at exercise prices of $6.49 and $4.14", "url": "https://www.stocktitan.net/sec-filings/FDMT/form-4-4d-molecular-therapeutics-inc-insider-trading-activity-a22f78de47b3.html", "source_name": "Stock Titan", "published_at": "2026-07-02T19:42:17", "published_display": "02 Jul 2026 19:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 4D Molecular Therapeutics For: 30 June By Investing.com", "summary": "This article from Investing.com reports the filing of Form 144 for 4D Molecular Therapeutics activity as of June 30. The content is very brief, serving primarily as a notice of the filing. It is surrounded by extensive financial market data, news headlines, and navigational eleme", "url": "https://ca.investing.com/news/stock-market-news/form-144-4d-molecular-therapeutics-for-30-june-93CH-4714990", "source_name": "Investing.com Canada", "published_at": "2026-07-01T12:10:40", "published_display": "01 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDMT - 4D Molecular Therapeutics Inc Latest SEC Filings", "summary": "This page provides a detailed financial overview and snapshot of 4D Molecular Therapeutics Inc (FDMT), including its latest stock performance, key financial metrics, insider and institutional ownership, and valuation ratios. The data highlights the company's recent strong perform", "url": "https://finviz.com/stock?t=FDMT&ta=1&p=w&ty=lf&page=3", "source_name": "Finviz", "published_at": "2026-07-01T12:10:40", "published_display": "01 Jul 2026 12:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4D Molecular Therapeutics to present 2-year Phase 2b trial results of gene therapy 4D-150 for wet AMD at ASRS 2026", "summary": "4D Molecular Therapeutics announced it will present two-year follow-up data from its PRISM Phase 2b clinical trial of 4D-150, a gene therapy for wet age-related macular degeneration (AMD), at the 44th Annual Scientific Meeting of the American Society of Retina Specialists in July", "url": "https://pluang.com/en/news-feed/4dmt-umumkan-presentasi-di-pertemuan-ilmiah-american-society-of-retina", "source_name": "Pluang", "published_at": "2026-06-30T20:39:46", "published_display": "30 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 90, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDMT (NASDAQ: FDMT) insider 10b5-1 sale of 9,810 shares for $117,720", "summary": "An affiliate of 4D Molecular Therapeutics, Inc. (FDMT) filed a Form 144 detailing insider sales. The filing reports a 10b5-1 sale by Scott Bizily of 9,810 shares for $117,720 on June 23, 2026, alongside an exercise of stock options for 5,752 shares and an Employee Stock Purchase ", "url": "https://www.stocktitan.net/sec-filings/FDMT/144-4d-molecular-therapeutics-inc-sec-filing-9caaaa8975e5.html", "source_name": "Stock Titan", "published_at": "2026-06-30T20:39:46", "published_display": "30 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists", "summary": "4D Molecular Therapeutics (4DMT) announced a podium presentation at the 44th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) in Montreal, Canada, from July 15-18, 2026. The presentation will provide a 2-year follow-up on the PRISM Phase 2b clinical ", "url": "https://www.globenewswire.com/news-release/2026/06/30/3320101/0/en/4dmt-announces-presentation-at-44th-annual-scientific-meeting-of-the-american-society-of-retina-specialists.html", "source_name": "GlobeNewswire", "published_at": "2026-06-30T19:39:46", "published_display": "30 Jun 2026 19:39", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4DMT to present 2-year PRISM trial follow-up at retina meeting", "summary": "4D Molecular Therapeutics (Nasdaq: FDMT) has announced a podium presentation at the 44th Annual Scientific Meeting of the American Society of Retina Specialists on July 18, 2026. The presentation will feature two-year follow-up data from the PRISM Phase 2b trial of its investigat", "url": "https://www.stocktitan.net/news/FDMT/4dmt-announces-presentation-at-44th-annual-scientific-meeting-of-the-6hosb21ldhft.html", "source_name": "Stock Titan", "published_at": "2026-06-30T19:39:46", "published_display": "30 Jun 2026 19:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4DMT completes enrollment in 4FRONT-2, global phase 3 trial of 4D-150 in wet AMD", "summary": "4D Molecular Therapeutics (4DMT) has completed enrollment in 4FRONT-2, a global Phase 3 trial for its gene therapy 4D-150 in patients with wet age-related macular degeneration (AMD). This over-enrollment, completed four months ahead of schedule, underscores significant interest i", "url": "https://www.ophthalmologytimes.com/view/4dmt-completes-enrollment-in-4front-2-global-phase-3-trial-of-4d-150-in-wet-amd", "source_name": "Ophthalmology Times", "published_at": "2026-06-30T14:40:54", "published_display": "30 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4DMT Completes 4FRONT-2 Enrollment for 4D-150 Gene Therapy in Wet AMD", "summary": "4D Molecular Therapeutics has completed enrollment for its global Phase 3 trial, 4FRONT-2, for the gene therapy candidate 4D-150 in wet age-related macular degeneration, four months ahead of schedule. The trial aims to achieve non-inferiority in visual acuity compared to afliberc", "url": "https://www.clinicaltrialvanguard.com/news/4dmt-completes-4front-2-enrollment-for-4d-150-gene-therapy-in-wet-amd/", "source_name": "The Clinical Trial Vanguard", "published_at": "2026-06-30T06:39:30", "published_display": "30 Jun 2026 06:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4DMT Secures Strategic Credit Facility for up to $200MM from Hercules Capital", "summary": "4D Molecular Therapeutics (4DMT) has secured a strategic credit facility of up to $200 million from Hercules Capital. This non-dilutive capital is expected to provide 4DMT with increased financial flexibility, supporting its operations into the second half of 2028 and advancing i", "url": "https://www.abfjournal.com/4dmt-secures-strategic-credit-facility-for-up-to-200mm-from-hercules-capital/", "source_name": "ABF Journal", "published_at": "2026-06-30T04:39:30", "published_display": "30 Jun 2026 04:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4D Molecular Therapeutics Shares Rise After New Credit Facility", "summary": "4D Molecular Therapeutics (NASDAQ:FDMT) shares increased following the announcement of a new Senior Secured Credit Facility worth $175 million from an investment fund managed by Blue Owl Capital. This financing is expected to extend the company's cash runway into 2027 and support", "url": "https://www.moomoo.com/news/post/72199244/4d-molecular-therapeutics-shares-rise-after-new-credit-facility", "source_name": "Moomoo", "published_at": "2026-06-30T01:40:53", "published_display": "30 Jun 2026 01:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: 4DMT Secures Strategic Credit Facility for up to $200 Million From Hercules Capital", "summary": "4D Molecular Therapeutics (4DMT) has secured a strategic credit facility for up to $200 million from Hercules Capital. This financing is intended to support the company's clinical pipeline development, including its lead product candidates, and provide working capital. The facili", "url": "https://www.moomoo.com/news/post/72189834/press-release-4dmt-secures-strategic-credit-facility-for-up-to", "source_name": "Moomoo", "published_at": "2026-06-30T00:42:17", "published_display": "30 Jun 2026 00:42", "sentiment": "positive", "sentiment_pct": 71, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4DMT SECURES STRATEGIC CREDIT FACILITY FOR UP TO $200 MILLION FROM HERCULES CAPITAL", "summary": "4D Molecular Therapeutics (4DMT) has secured a credit facility of up to $200 million from Hercules Capital. This funding is intended to support the clinical development and manufacturing of 4DMT's targeted AAV gene therapy pipeline, particularly focusing on late-stage clinical pr", "url": "https://www.moomoo.com/news/flash/22715160/4dmt-secures-strategic-credit-facility-for-up-to-200-million", "source_name": "Moomoo", "published_at": "2026-06-29T19:11:55", "published_display": "29 Jun 2026 19:11", "sentiment": "positive", "sentiment_pct": 82, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4D Molecular Therapeutics Completes Enrollment in Phase 3 Wet AMD Trial", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/4d-molecular-therapeutics-completes-enrollment-124323164.html", "source_name": "MT Newswires", "published_at": "2026-06-29T12:43:23+00:00", "published_display": "29 Jun 2026 12:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4D Molecular Therapeutics Completes Enrollment for 4Front-2 Global Phase 3 Clinical Trial of 4D-150 in Wet Amd", "summary": "4D Molecular Therapeutics has completed enrollment for its 4FRONT-2 global Phase 3 clinical trial of 4D-150 for wet age-related macular degeneration (wet AMD) approximately four months ahead of schedule. The trial over-enrolled patients, with final randomization expected in Q3 20", "url": "https://www.marketscreener.com/news/4d-molecular-therapeutics-completes-enrollment-for-4front-2-global-phase-3-clinical-trial-of-4d-150-ce7f5fded08ef323", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T13:11:54", "published_display": "29 Jun 2026 13:11", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4D Molecular Therapeutics (FDMT) signs up to $200M secured loan with Hercules", "summary": "4D Molecular Therapeutics, Inc. (FDMT) has secured a senior loan of up to $200 million from Hercules Capital, with an initial draw of $20 million and additional tranches tied to milestones. The loan matures on June 1, 2031, carries floating interest rates with floors of 8.75% to ", "url": "https://www.stocktitan.net/sec-filings/FDMT/8-k-4d-molecular-therapeutics-inc-reports-material-event-aa25bfd37ca4.html", "source_name": "Stock Titan", "published_at": "2026-06-29T12:11:55", "published_display": "29 Jun 2026 12:11", "sentiment": "positive", "sentiment_pct": 61, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4DMT finishes Phase 3 enrollment for wet AMD gene therapy trial", "summary": "4D Molecular Therapeutics (4DMT) has completed enrollment for its 4FRONT-2 global Phase 3 clinical trial for 4D-150 in wet AMD, approximately four months ahead of schedule and with over 500 patients. This milestone, along with the ongoing 4FRONT-1 trial, positions 4DMT to potenti", "url": "https://www.stocktitan.net/news/FDMT/4dmt-completes-enrollment-for-4front-2-global-phase-3-clinical-trial-9hbsdoided79.html", "source_name": "Stock Titan", "published_at": "2026-06-29T12:11:54", "published_display": "29 Jun 2026 12:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD", "summary": "4D Molecular Therapeutics (4DMT) announced the completion of enrollment for its 4FRONT-2 global Phase 3 clinical trial of 4D-150 for wet age-related macular degeneration (wet AMD), approximately four months ahead of schedule and with over-enrollment. This marks the second complet", "url": "https://www.globenewswire.com/news-release/2026/06/29/3318897/0/en/4dmt-completes-enrollment-for-4front-2-global-phase-3-clinical-trial-of-4d-150-in-wet-amd.html", "source_name": "GlobeNewswire", "published_at": "2026-06-29T12:11:54", "published_display": "29 Jun 2026 12:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4D Molecular (NASDAQ: FDMT) CLO exercises options, sells 9,810 shares at $12", "summary": "4D Molecular Therapeutics' Chief Legal Officer, Scott Bizily, exercised options to acquire 9,810 shares at $4.14 per share and then sold all of them on the open market at $12.00 per share on June 23, 2026. Following these transactions, Bizily holds 18,427 common shares directly a", "url": "https://www.stocktitan.net/sec-filings/FDMT/form-4-4d-molecular-therapeutics-inc-insider-trading-activity-9fb6a7e1d03f.html", "source_name": "Stock Titan", "published_at": "2026-06-25T20:39:18", "published_display": "25 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Strength Seen in 4D Molecular Therapeutics (FDMT): Can Its 7.9% Jump Turn into More Strength?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQZDR2V2UyZFltdXprY3FlUktWNnRUdVdlaFJsVVhZeHlTMV9vRkxQRnMwREtIUW9xdVNqWWZjUDI5cjV2M2U0SXpFWWJ6ZzQwNVczR3AwWklPSnhFbG05LTVUQWtnaGJEOVY4R2dCUUwwQTBIbTRJYmdadE5zSk1iS0FYd0ExXzFhNFN5RVYyeDlZRnZmbFJpWkJaMC1IbHZobFJrSDAzQQ?oc=5", "source_name": "Market source", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider David Kirn sells 114,746 4D Molecular Therapeutics (FDMT) shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOUWJtZ0ZxYllZRE00elBGbHptR0NxTV84cmxVVUxOQWlKN0lnMFY2WVhPckZwTmZrY0tSMGJQRzdVTlZqbWFlcUVYOGFFN19RM3hZbHJGSkx4YlZWZlJ6amduaGgtVENtalg5dlhOa2JKeEFFRUVkcE90T0owUHQ0SlRUVWViNkFlRUExTkx3OVFJMlA1MXIwaHdjVGFHSDRIT09seDZkczhiaFJyWElJdngtSWE0SUhEaHRIbjRDZFQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4D Molecular Therapeutics (FDMT) director granted 50,000 stock options with CIC vesting", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPenVTLTQ1M3FBcmFpWkFneGUwdEtqMk1uYXJhM0hnMXA2MFZGNEFuYW1BTUtkTmpla1Y3UmFheEpFZmc5cS1NbUZNTDViZUVuck5iRDNzd1pmeDltZm5jaG4wbVB0OTc0c1dsYUtNUXJIMmFHcjZuZndyU2xPRlN0Rm5Rc3l0dDE5TTU3Y2RDdy1aNkdDWTN0M0JyZ0NMMnNTMmE4bmdJT3hwMkNUSWlBNnFBYjF1eFV4NHdwa0N5OUg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4D Molecular (FDMT) grants director 50,000 stock options at $9.42", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOb2JfN01IN0dpSEpoS0pRVzAxNnJ6TG9iaVBFRDZrYkJHc0pXUU9FS0pia3FnQmI0dWE5VExjdkE5RTB2MGdjNEZFdnMzUFo0aHY0aVpVSHZrcWgwcjJ3NDV2dTZoMHR5dmdOaTJTWXg1cUdDZ2U5SGtRazM2YUxmbkVJSDJmMlVZVVpsai1JYW9yaE1sdjlyXzZVai1lSnMwMzI4UWduU3RGaV9XcFJURzhTbUNyTl9NMlVXQy1pT0Y?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4D Molecular Therapeutics Inc (FDMT): Gene Therapy Stock Made for You?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNcURKLWlCMXE2dDZXWGxrbEpObmpONUg4ek5fZWtrVXNva1AwNDFDXzZmZTJ6THh0dVpJd3RHQjhLWnFBZnFtelZ1ckFxWENLSFlpRG56SVl1TDh1Zl8zaURhR3M0SG42ZGtlbThpdXdmVXYzWFZBTnE4X0xOR21NU2xvT2V3dDlvdXRfdG9jSFhHWjB6eEZRanUxY0VGWUtWMWFERV9n?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Have Made A Financial Statement On 4D Molecular Therapeutics, Inc.'s (NASDAQ:FDMT) First-Quarter Report", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQNXdJMG0yN2ZWQ1p5eXpUU1B4bWRIYURuR1RDYWI0QS1NZHUxVHR5aFpGaGVpWGpFYmhmckx5MnRUb2ZkaFljX2tCeW5pZ25NSFNLU1d2OTAxakhacGd2QzFxbVFJQVI2TWRRX2hQcEsydjQ1MEZnRnE1cTVsVnJsZ0ZfQXo5MjJMSlE2cm5CdEZUa1NvcFVoWjRGcUNkc25La1pr?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQNHBoRWVVYmp2SUpCX3ZmWjhxMDFVUVdwSE5kSzlpdDh4UTdKTC1kLXpZNy0xLU1SLVJ2RUNBc212SVJDbU1CREJqZzRLZzMwd2pYQlFaR0FHRGgyVEhVclpfTzMtNXFVRXVtc1dEV25xN3JvWGhRblBBeGVFRmttWmktcktVeC0tdXFZVVBpZHNkblVMYTlTUzRNb2t6RjdnS1pZQUhR?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4D Molecular Therapeutics, Inc. Common Stock (FDMT) Stock Price Today: $11.70", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE9NMF9INXdqMlROanpUTUswMk5uVFdsN282X1htMEZ5NklmSXJEUDZVNmdlS2NZWkRsRWV2aExzRUY1WHVWYkhUOU13TmhlbDd0b3lUYTVoYw?oc=5", "source_name": "Gotrade", "published_at": "2026-01-13T02:30:02+00:00", "published_display": "13 Jan 2026 02:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Everyone Is Watching 4D Molecular Therapeutics, Inc. (FDMT) Closely", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxQZGdmbENQQlNiZnZENGs4NG95Z3c1QXoxWmFoOGxZdHlMMm9jLVZaZUxkUDZwMkZzZG10Ni1rNnlMTUdkLU1RY2lMaG43NVdHY054QzU2UHVfTjJPQjJyX3ZPV3BQNE1uWm1EdVFHcFE3aFFJOGZvSDNOWjkwQ3h4OVlvOWdCQU0?oc=5", "source_name": "Market source", "published_at": "2025-12-27T08:00:00+00:00", "published_display": "27 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is 4D Molecular Therapeutics (NASDAQ:FDMT) In A Good Position To Invest In Growth?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxOSlptUzBCRTAzdTNtZXl5U1BGMndia2RhQzdZc2txOTNvb2YtWGlzX3QyZjlBQ0xiV1h4OGR2eGpBRFN6dmJ3eFJja2tDenMwQ2kxR015ekZJd0wya1dxMXBWaGVhMjl0d3RXWkxqQWs3RGhKRzNIWTRLdTBucHNMU2ZCaC1ITmk1V2Zv?oc=5", "source_name": "Market source", "published_at": "2025-10-03T07:00:00+00:00", "published_display": "03 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "4D Molecular Therapeutics (FDMT) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFB1VnBKcEFzMHFhQmltSE9zQ3NMX2tUY3Flb3BaZVVDcktZNjZpcjJBc0pnTnhNR1daQmVaMzFHa0s3cmcyb0VrVmhFWDBpY0RBMmZz?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T01:19:59+00:00", "published_display": "25 Apr 2025 01:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 91, "total_relevant": 46, "sentiment_summary": {"positive": 16, "negative": 5, "neutral": 25, "score": 58, "total": 46, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 14.85, "count": 27}, {"event": "earnings", "label": "Earnings", "weight": 6.05, "count": 13}, {"event": "liquidity", "label": "Balance sheet", "weight": 2.2, "count": 4}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.55, "count": 1}], "positive_events": 16, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 12.31, "latest_week": "2026-07-10", "one_week_move": -5.3, "four_week_move": 39.4, "twelve_week_move": 17.3, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.961945, "market_dynamics_buy_signal": false, "relative_strength": 19.102474, "fair_value_gap": 1.2, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "negative", "expectation_probability": 44.1358, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-5.3% over one week, +39.4% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 68, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 12}, {"label": "Market source", "count": 11}, {"label": "Finviz", "count": 3}, {"label": "Moomoo", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "Investing.com Nigeria", "count": 2}, {"label": "TradingView", "count": 2}, {"label": "GlobeNewswire", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 38}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 27}, {"label": "Earnings", "count": 13}, {"label": "Balance sheet", "count": 4}, {"label": "Analyst action", "count": 1}, {"label": "Macro sensitivity", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "38", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-5.3% over one week, +39.4% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "4D Molecular Therapeutics (NASDAQ: FDMT) insider executes 58K-share 10b5-1 sale"}], "updated_at": "2026-07-16T11:59:41.063491+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}